20/20 Biolabs Inc. AIDX
- Market cap
- $5.4M
- P/E
- 0.0×
Follow AIDX
Target Price Range
Analyst price targets
Free account| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| — | — | — | — | — | — | — | — | — | — |
Analyst estimates 2026–2028 Powerpack |
Low Price | ||
| — | — | — | — | — | — | — | — | — | — | High Price | |||
| — | — | — | — | — | — | — | — | 14 | 14 |
Employees
|
|||
| — | — | — | — | — | — | — | — | 0 | 0 |
Revenue/Emp
|
|||
| — | — | — | — | — | — | — | — | 2 | 2 |
Revenue
|
|||
| — | — | — | — | — | — | — | — | 20.56% | 29.56% |
Gross Margin
|
|||
| — | — | — | — | — | — | — | — | (6) | (4) |
EBT
|
|||
| — | — | — | — | — | — | — | — | (316.82%) | (182.82%) |
EBT Margin
|
|||
| — | — | — | — | — | — | — | — | (6) | (4) |
Net Income
|
|||
| — | — | — | — | — | — | — | — | 0 | 0 |
Depreciation
|
|||
| — | — | — | — | — | — | — | — | 0.37 | 0.41 |
Revenue/Sh
|
|||
| — | — | — | — | — | — | — | — | (1.16) | (0.76) |
Earnings/Sh
|
|||
| — | — | — | — | — | — | — | — | (0.54) | (0.39) |
Cash Flow/Sh
|
|||
| — | — | — | — | — | — | — | — | 0.00 | 0.00 |
Capex/Sh
|
|||
| — | — | — | — | — | — | — | — | (0.54) | (0.39) |
Free CF/Sh
|
|||
| — | — | — | — | — | — | — | — | 0.31 | 0.00 |
Book Value/Sh
|
|||
| — | — | — | — | — | — | — | — | 5 | 5 |
Shares
|
|||
| — | — | — | — | — | — | — | — | 0.00 | 0.00 |
PE Ratio
|
|||
| — | — | — | — | — | — | — | — | 0.00 | 0.00 |
PS Ratio
|
|||
| — | — | — | — | — | — | — | — | 0.00 | 0.00 |
PB Ratio
|
|||
| — | — | — | — | — | — | — | — | 0.00 | 0.00 |
EV/Sales
|
|||
| — | — | — | — | — | — | — | — | (20.70) | (20.70) |
EV/FCF
|
|||
| — | — | — | — | — | — | — | — | (3) | (2) |
Op' Cash Flow
|
|||
| — | — | — | — | — | — | — | — | — | — | Capex | |||
| — | — | — | — | — | — | — | — | (3) | (2) |
FCF
|
|||
| — | — | — | — | — | — | — | — | 1 | (1) |
Working Cap'
|
|||
| — | — | — | — | — | — | — | — | — | 1 |
Total Debt
|
|||
| — | — | — | — | — | — | — | — | (2) | 0 |
Net Debt
|
|||
| — | — | — | — | — | — | — | — | 2 | 0 |
Sh' Equity
|
|||
| — | — | — | — | — | — | — | — | 0.00% | (96.84%) |
ROA
|
|||
| — | — | — | — | — | — | — | — | 0.00% | 0.00% |
ROIC
|
|||
| — | — | — | — | — | — | — | — | 0.00% | (537.07%) |
ROE
|
|||
20/20 Biolabs Inc. (AIDX) key facts
- 20/20 Biolabs Inc.’s revenue for fiscal 2025 (year ended December 2025) was $2.0 million, up 16.7% from fiscal 2024.
- As of September 25, 2026, AIDX traded at $0.43, a market capitalization of $5.4 million.
- Return on equity was −537.1% and debt-to-equity 0.00.
20/20 Biolabs Inc. (AIDX) Latest News
5 Sep
Healwell AI (TSX:AIDX) stock receives fresh price target split after quarterly results. Quarterly results trigger new analyst price targets that may shift near-term AIDX market sentiment without major strategic changes.
17 Aug
20/20 BioLabs reports Q2 2026 financial results and operational progress with cancer test revenue hitting a record quarterly level. Record cancer test revenue signals strong commercial traction that can materially boost future growth and investor sentiment.
9 Jul
20/20 BioLabs Inc. (AIDX) highlights an investor webinar on OneTest™ for Medicare and serial biomarker tracking alongside strong Q2 revenue growth. Webinar focus on Medicare access and biomarker tracking plus Q2 revenue growth indicates major strategic and financial momentum.
27 May
20/20 Biolabs Inc. (AIDX) multi-cancer early detection blood test selected by Vermont state to screen up to 4,500 firefighters. State screening contract delivers moderate validation and incremental revenue potential without major trajectory shift.
20 May
20/20 BioLabs reported first quarter 2026 financial results and recent operational progress. Quarterly results and operational updates supply performance data that moderately shapes near-term investor views.
12 May
20/20 BioLabs Inc. exclusively licenses PSA Velocity Algorithm from University of South Carolina. Exclusive licensing of PSA Velocity Algorithm enables major advancements in diagnostic offerings and market positioning.
7 Apr
20/20 BioLabs has been selected by Evexia Diagnostics to offer OneTest™ for Cancer through the Evexia platform. Partnership expands OneTest distribution and market access.
31 Mar
20/20 BioLabs Inc. (AIDX) reported full year 2025 financial results and recent operational progress. Full-year financial results and operational updates typically drive material shifts in valuation and investor outlook.
27 Mar
Maryland fire departments received $520,000 to conduct cancer screenings with 20/20 BioLabs’ OneTest multi-cancer early detection blood test. Award provides product validation and adoption by fire departments that can support revenue growth for 20/20 Biolabs.
24 Mar
20/20 BioLabs secures exclusive U.S. license from ROKIT Healthcare to integrate advanced CKD prediction technology into its longevity test program. Exclusive license enables CKD prediction integration that strengthens longevity test offerings and market positioning.
22 Mar
Revised targets and growth assumptions are altering Healwell AI (TSX:AIDX) investment outlook. Recut targets and growth assumptions can shift investor sentiment and near-term valuation for AIDX.
19 Mar
HEALWELL AI posts record revenue and first positive adjusted EBITDA year as global AI platform strategy advances. Record revenue and positive EBITDA mark major financial milestone with direct boost to company trajectory and investor outlook.
12 Mar
20/20 BioLabs Inc. (AIDX) highlights advantages of its patented protein biomarker technology for multi-cancer early detection referencing recent studies. Company promotion of its detection technology may moderately lift investor sentiment and visibility.